Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: A feasible and effective salvage treatment for lymphoid malignancies

Oncology Reports

Volumn 14, Issue 4, 2005, Pages 933-940

  Clavio, Marino ^a   Garrone, Alberto ^a   Pierri, Ivana ^a   Michelis, Gian Luca ^a   Balocco, Manuela ^a   Albarello, Alessandra ^a   Varaldo, Riccardo ^a   Canepa, Paolo ^a   Miglino, Maurizio ^a   Ballerini, Filippo ^a   Canepa, Letizia ^a   Gobbi, Marco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Autologous peripheral blood stem cell transplant; Epirubicin; Etoposide; Ifosfamide; non Hodgkin's lymphoma; Salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEAM PROTOCOL; CARMUSTINE; CD34 ANTIGEN; CYTARABINE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MITOXANTRONE; PODOPHYLLOTOXIN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; METHODOLOGY; MIDDLE AGED; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENT DISEASE; REMISSION; RISK; SALVAGE THERAPY; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; IFOSFAMIDE; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; MITOXANTRONE; MULTIPLE MYELOMA; ODDS RATIO; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PODOPHYLLOTOXIN; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; TIME FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 33644828103     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.4.933     Document Type: Article

References (25)

1. Armitage JO: Treatment strategies for patients with relapsed or refractory Hodgkin's disease. Ann Oncol 6: 517-518, 1995.
2. Salles G, Shipp MA and Coiffier B: Chemotherapy of non-Hodgkin's aggressive lymphomas. Semin Hematol 31: 46-69, 1994. (Pubitemid 24031131)
3. Sweetenham JW, Carella AM, Taghipour G, et al. High dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 17: 3101-3109, 1999. (Pubitemid 29470638)
4. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD and Horning SJ: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89: 814-822, 1997. (Pubitemid 27121274)
5. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333: 1540-1545, 1995.
6. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12: 1169-1176, 1994. (Pubitemid 24173930)
7. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71: 117-122, 1988. (Pubitemid 18050400)
8. Rodriguez MA, Cabanillas FC, Hagemeister FB, McLaughlin P, Romaguera JE, Swan F and Velasquez W: A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 6: 609-611, 1995.
9. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS and Cabanillas F: MIME chemotherapy (methyl- GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5: 556-561, 1987. (Pubitemid 17062492)
10. Case DC Jr, Anderson J, Ervin TJ and Gottlieb A: Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma. Cancer and Leukemia Group B study 8552. Hematol Oncol 9: 189-196, 1991.
11. Engert A, Schnell R, Kupper F, et al. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma. Leuk Lymphoma 24: 513-522, 1997. (Pubitemid 27182206)
12. Zinzani PL, Barbieri E, Visani G, et al. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica 79: 508-512, 1994.
13. Zinzani PL, Tani M, Molinari AL, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 87: 816-821, 2002. (Pubitemid 34851551)
14. Proctor SJ, Taylor PR, Angus B, et al. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Eur J Haematol 64: S28-S32, 2001.
15. Anselmo AP, Meloni G, Cavalieri E, et al. Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients. Ann Hematol 79: 79-82, 2002.
16. Mills W, Chopra R, McMillan A, Pearce R, Linch DC and Goldstone AH: BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 13: 588-595, 1997.
17. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244-1257, 1999.
18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982. (Pubitemid 13149996)
19. Kaplan EL and Meier P: Non-parametric estimation from incomplete observation. JAMA 53: 457-481, 1952.
20. Shipp MA: On behalf of the International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive Non Hodgkin's Lymphoma. N Engl J Med 329: 987-994, 1993. (Pubitemid 23307906)
21. Pocali B, De Simone M, Annunziata M, et al. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 45: 1605-1609, 2004. (Pubitemid 38886003)
22. O'Connell N, Gardiner N, Duggan C, et al. Effective progenitor cell mobilization in lymphoproliferative disorders using ifosfamide, epirubicin and etoposide (IEV). Eur J Haematol 64: 33-36, suppll 2001.
23. Straka C, Hebart H, Adler-Reichel S, Werding N, Emmerich B and Einsele H: Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma. Oncology 65 (Suppl 2): 94-98, 2003. (Pubitemid 37346740)
24. Joyce RM, Regan M, Ottaway J, et al. Phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDCASCT). Ann Oncol 14 (Suppl 1): 21-27, 2003.
25. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103: 3684-3688, 2004. (Pubitemid 38596282)